Preliminary dinical trial resuhs of CD19/CD22 targeted CARs for treatment of ALL/DLBCL and CD19/BCMA targeted for multiple myeloma have demonstrated promising efficacy*'. This evidence concerns the gene TNFRSF17 and AL amyloidosis.